Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biora Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BIOR
Nasdaq
8731
https://www.bioratherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biora Therapeutics Inc
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
- Apr 8th, 2024 12:00 pm
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
- Apr 4th, 2024 12:00 pm
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Apr 3rd, 2024 8:05 pm
Biora Therapeutics Full Year 2023 Earnings: Beats Expectations
- Apr 1st, 2024 7:39 pm
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Apr 1st, 2024 12:00 pm
BIOR: Negotiations Accelerating
- Mar 27th, 2024 4:35 pm
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript
- Mar 27th, 2024 4:18 pm
Q4 2023 Biora Therapeutics Inc Earnings Call
- Mar 27th, 2024 10:18 am
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Mar 26th, 2024 8:05 pm
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
- Mar 18th, 2024 12:00 pm
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
- Mar 11th, 2024 12:00 pm
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
- Feb 26th, 2024 1:00 pm
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
- Feb 8th, 2024 1:00 pm
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
- Jan 22nd, 2024 1:00 pm
Biora Therapeutics Provides Outlook for 2024
- Jan 16th, 2024 1:00 pm
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
- Jan 8th, 2024 1:00 pm
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
- Jan 2nd, 2024 1:00 pm
BIOR: Capitalizing on Progress: BT-600 to Start
- Dec 20th, 2023 10:21 am
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
- Dec 19th, 2023 1:00 pm
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
- Dec 18th, 2023 1:00 pm
Scroll